IDXX
IDEXX Laboratories, Inc.
$570.21
Platform & Compounding FCF
65%
Two-stage FCF DCF
Strong
·
Conviction
Overvalued
Trading 123.4% above fair value
You pay
$570.21
Bear
$186.40
Fair
$255.29
Bull
$323.29
Bear
$186.40
-67.3%
6% stage 1 growth, 12% discount
Fair
$255.29
-55.2%
10% stage 1 growth, 12% discount
Bull
$323.29
-43.3%
14% stage 1 growth, 12% discount
Adjust Assumptions
10.4%
12.0%
3.0%
Key Value Driver
FCF growth rate (10% base case)
Terminal Value % of EV
35%
Implied Market Multiple
42.3x
Market is pricing in (growth)
21.0%
vs 10.4% base
Analyst Consensus (External Reference)
Never blended into the bear/base/bull estimates above.
Average Target (23 analysts)
$690.00
Divergence from AlphaVal
63%
Summary
Using a two-stage FCF DCF with 10% growth decelerating over 15 years, discounted at 12%, the base-case intrinsic value is $255.29 per share.
Warnings
Wall Street's average price target is $690.00 (from 23 analysts). Our estimate is 63% below the consensus -- consider that gap carefully.
Key Risks
- P/E alone misleads — earnings depressed by growth investment
- Cyclical or commodity businesses may be misclassified as platforms
- Terminal value dominance suggests sensitivity to long-run assumptions